Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 19:15:1454348.
doi: 10.3389/fphar.2024.1454348. eCollection 2024.

Oxylipins as therapeutic indicators of herbal medicines in cardiovascular diseases: a review

Affiliations
Review

Oxylipins as therapeutic indicators of herbal medicines in cardiovascular diseases: a review

Mengqi Li et al. Front Pharmacol. .

Abstract

Globally, cardiovascular diseases (CVDs) remain the leading cause of death, and their prevention and treatment continue to face major challenges. Oxylipins, as novel circulating markers of cardiovascular disease, are crucial mediators linking cardiovascular risk factors such as inflammation and platelet activation, and they play an important role in unraveling cardiovascular pathogenesis and therapeutic mechanisms. Chinese herbal medicine plays an important role in the adjuvant treatment of cardiovascular diseases, which has predominantly focused on the key pathways of classic lipids, inflammation, and oxidative stress to elucidate the therapeutic mechanisms of cardiovascular diseases. However,The regulatory effect of traditional Chinese medicine on oxylipins in cardiovascular diseases remains largely unknown. With the increasing number of recent reports on the regulation of oxylipins by Chinese herbal medicine in cardiovascular diseases, it is necessary to comprehensively elucidate the regulatory role of Chinese herbal medicine in cardiovascular diseases from the perspective of oxylipins. This approach not only benefits further research on the therapeutic targets of Chinese herbal medicine, but also brings new perspectives to the treatment of cardiovascular diseases.

Keywords: cardiovascular disease; herbal medicine; oxylipins; polyunsaturated fatty acids; review.

PubMed Disclaimer

Conflict of interest statement

Author YL was employed by Changchun Sino-Russian Science and Technology Park Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Enzymatic pathways of oxylipins generation.
FIGURE 2
FIGURE 2
Disrupted Oxylipins in Cardiovascular Disease and Oxylipins Targets in Chinese Herbal Medicine. This Sangi diagram is used to demonstrate the oxylipin targets of cardiovascular disease and Chinese herbal medicine, providing a comprehensive overview of the regulation of oxylipins by Chinese herbal medicine in cardiovascular disease.

Similar articles

References

    1. Adams J. W., Sah V. P., Henderson S. A., Brown J. H. (1998). Tyrosine kinase and c-Jun NH2-terminal kinase mediate hypertrophic responses to prostaglandin F2alpha in cultured neonatal rat ventricular myocytes. Circ. Res. 83, 167–178. 10.1161/01.res.83.2.167 - DOI - PubMed
    1. Alonso-Galicia M., Falck J. R., Reddy K. M., Roman R. J. (1999). 20-HETE agonists and antagonists in the renal circulation. Am. J. Physiol. 277, F790–F796. 10.1152/ajprenal.1999.277.5.F790 - DOI - PubMed
    1. Bannehr M., Löhr L., Gelep J., Haverkamp W., Schunck W.-H., Gollasch M., et al. (2019). Linoleic acid metabolite DiHOME decreases post-ischemic cardiac recovery in murine hearts. Cardiovasc Toxicol. 19, 365–371. 10.1007/s12012-019-09508-x - DOI - PubMed
    1. Beccacece L., Abondio P., Bini C., Pelotti S., Luiselli D. (2023). The link between prostanoids and cardiovascular diseases. Int. J. Mol. Sci. 24, 4193. 10.3390/ijms24044193 - DOI - PMC - PubMed
    1. Belvisi M. G., Mitchell J. A. (2009). Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br. J. Pharmacol. 158, 994–1003. 10.1111/j.1476-5381.2009.00373.x - DOI - PMC - PubMed

LinkOut - more resources